Mechanisms of Retinal Vascular Permeability in Diabetes
糖尿病视网膜血管通透性的机制
基本信息
- 批准号:7220571
- 负责人:
- 金额:$ 32.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-09-01 至 2009-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAngiotensin IIAngiotensin II ReceptorBiological AssayBlindnessBlood-Retinal BarrierCalcium ChannelCell membraneChemicalsComplementary DNAConditionCultured CellsDataDevelopmentDiabetes MellitusDiabetic RetinopathyDominant-Negative MutationEndothelial CellsEndotheliumGoalsHormonalHydrostatic PressureHyperglycemiaHypertensionHypotensionImpairmentIn VitroInbred SHR RatsLeadLocalizedMeasuresModelingMolecularPatientsPermeabilityPhosphorylationPropertyProtein Kinase CProteinsRateRattusReceptor ActivationRegulationResearchResearch PersonnelRetinalRisk FactorsRoleSerine/Threonine PhosphorylationSignal PathwaySignal TransductionSignal Transduction PathwayStarling (law)TestingTight JunctionsTransfectionVascular DiseasesVascular Endothelial Growth Factor ReceptorVascular Endothelial Growth FactorsVascular PermeabilitiesVisionWaterWestern Blottingbasediabeticdiabetic rathuman NOS3 proteinimmunocytochemistryimprovedin vivoin vivo Modelinsightinstrumentmacular edemamonolayernoveloccludinpressureprotein expressionsolute
项目摘要
DESCRIPTION (provided by applicant): Diabetic retinopathy is a leading cause of vision impairment and is exacerbated by hypertension. Vision impairment results from increased retinal vascular permeability and macular edema. The overall goal of this project is to understand how diabetes and hypertension interact to impair vision. The specific objectives are to identify the mechanisms by which chemical (VEGF, angiotensin II) and physical factors (increased hydrostatic pressure) increase retinal vascular permeability. In the initial four years of this project the investigators have shown that VEGF and diabetes alter the expression and phosphorylation of endothelial tight junction proteins concomitant with increased blood-retinal barrier (BRB) permeability. Preliminary studies demonstrate that VEGF, angiotensin II and hyperglycemia impair endothelial cell signaling pathways to tight junctions. In addition, experimental hypertension exerts physical forces on endothelium. The project will investigate the signal transduction pathways by which VEGF, angiotensin II and pressure forces increase BRB permeability. The general hypothesis is proposed that diabetes and hypertension impair blood-retinal barrier integrity via effects on endothelial tight junction proteins. Three specific aims will test the hypothesis: first, to determine the mechanism by which VEGF regulates tight junction protein phosphorylation and retinal vascular permeability; second, to determine the mechanism by which elevated transmural hydrostatic pressure impairs BRB integrity; and third, to investigate the mechanism by which hypertension accelerates blood-retinal barrier breakdown in diabetic rats. A combination of cell culture, ex vivo and in vivo models will be used. The rationale for this research is that understanding the molecular mechanisms of BRB regulation will provide improved means to control vascular permeability and vision loss in diabetes and other retinal vascular diseases.
描述(申请人提供):糖尿病视网膜病变是视力受损的主要原因,高血压会加重。视力障碍是由于视网膜血管通透性增加和黄斑水肿造成的。这个项目的总体目标是了解糖尿病和高血压是如何相互作用损害视力的。其具体目标是确定化学因素(血管内皮生长因子、血管紧张素II)和物理因素(增加静水压力)增加视网膜血管通透性的机制。在该项目的最初四年中,研究人员表明,血管内皮生长因子和糖尿病改变了内皮紧密连接蛋白的表达和磷酸化,并伴随着血-视网膜屏障(BRB)通透性的增加。初步研究表明,血管内皮细胞生长因子、血管紧张素II和高血糖会损害内皮细胞紧密连接的信号通路。此外,实验性高血压对血管内皮细胞施加物理作用力。该项目将研究血管内皮生长因子、血管紧张素II和压力增加BRB通透性的信号转导途径。一般的假设是糖尿病和高血压通过影响内皮紧密连接蛋白来损害血-视网膜屏障的完整性。三个特定的目标将检验这一假说:第一,确定血管内皮生长因子调节紧密连接蛋白磷酸化和视网膜血管通透性的机制;第二,确定跨壁静水压升高损害BRB完整性的机制;第三,探讨高血压加速糖尿病大鼠血-视网膜屏障破坏的机制。将采用细胞培养、体外和体内模型相结合的方式。这项研究的基本原理是,了解BRB调节的分子机制将为控制糖尿病和其他视网膜血管疾病的血管通透性和视力损失提供更好的手段。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Antonetti其他文献
David Antonetti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Antonetti', 18)}}的其他基金
The role of heme in retinal vascular development and disease
血红素在视网膜血管发育和疾病中的作用
- 批准号:
10568168 - 财政年份:2023
- 资助金额:
$ 32.49万 - 项目类别:
Discovering novel atypical PKC inhibitors as in vivo chemical probes - Supplement to Promote Diversity
发现新型非典型 PKC 抑制剂作为体内化学探针 - 促进多样性的补充
- 批准号:
9196555 - 财政年份:2016
- 资助金额:
$ 32.49万 - 项目类别:
Mechanisms of Retinal Vascular Permeability in Diabetes
糖尿病视网膜血管通透性的机制
- 批准号:
10219254 - 财政年份:1998
- 资助金额:
$ 32.49万 - 项目类别:
Mechanisms of Retinal Vascular Permeability in Diabetes
糖尿病视网膜血管通透性的机制
- 批准号:
8989102 - 财政年份:1998
- 资助金额:
$ 32.49万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 32.49万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 32.49万 - 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 32.49万 - 项目类别:
Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
- 批准号:
19K17401 - 财政年份:2019
- 资助金额:
$ 32.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
- 批准号:
411570 - 财政年份:2019
- 资助金额:
$ 32.49万 - 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
- 批准号:
391615 - 财政年份:2018
- 资助金额:
$ 32.49万 - 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
- 批准号:
26460229 - 财政年份:2014
- 资助金额:
$ 32.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
- 批准号:
25870715 - 财政年份:2013
- 资助金额:
$ 32.49万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8531707 - 财政年份:2012
- 资助金额:
$ 32.49万 - 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8397394 - 财政年份:2012
- 资助金额:
$ 32.49万 - 项目类别: